Compare Hasbro, Inc. (HAS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Natera Inc. Common Stock — how do they compare? Hasbro, Inc. trades at $96.2 (market cap $13.53B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.2× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 2.92% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Natera Inc. Common Stock for 0 Days on average.
| HAS | NTRA | |
|---|---|---|
Market Cap | $13.53B | $57.03B |
Volume | 1,762,034 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $425.64 |
52-Week Low | $74.13 | $179.42 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $15.72B | $56.18B |
Dividend Yield | 2.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $95.46, up 0.77% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings beats in recent quarters (Q4 2025-Q2 2026) and positive cash flow trends, though 2025 net income was negative. Valuation metrics include a P/E of 17.07 and P/S of 2.74, while institutional interest remains high with recent purchases by HSBC and Virginia Retirement Systems.
Outlook is positive with a consensus price target of $107.60 (13% upside), supported by Magic: The Gathering growth and cost savings. Risks include high debt levels (debt-to-asset ratio of 59.09% in 2025) and sensitivity to consumer spending trends. The upcoming Q3 2026 earnings on October 20 will be a key catalyst.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
